Process Development Engineer 1 at Akston Biosciences Corporation - Beverly, MA, US
Akston Biosciences Corporation leverages its novel fusion protein platform to develop and manufacture new classes of biologics, including vaccines, ultra-long-acting insulins, and autoimmune disease therapies. Founded by the team that developed the world's first clinical glucose-responsive insulin at SmartCells, Inc., Akston's COVID-19 vaccine candidate is in Phase II trials in the Netherlands. It has partnered with Dechra Pharmaceuticals PLC to commercialize once-a-week canine and feline insulin therapies. The company employs 35 people, has over 3,500 ft2 of research laboratory space and a 12,400 ft2 GMP clean room biologics manufacturing facility.